Cerevance to Present at the 31st Annual Piper Jaffray Healthcare Conference
BOSTON--(BUSINESS WIRE)--Nov 26, 2019--
Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, today announced that Brad Margus, chief executive officer, will present the company’s target discovery and clinical development work during the 31st Annual Piper Jaffray Healthcare Conference taking place December 3-5, 2019 in New York, NY.
Date: Wednesday, December 4, 2019
Time: 9:10-9:30 a.m. ET
Location: New York, NY
The 31st Annual Piper Jaffray Healthcare Conference showcases senior management teams from leading public and private companies delivering presentations to an audience of institutional investors, equity portfolio managers and research analysts.
Cerevance is a private pharmaceutical company focused on central nervous system diseases. The company’s powerful NETSseq target discovery platform is being applied to a growing collection of more than 6,000 human brain tissue samples, yielding a pipeline of novel discovery-stage and clinical-stage compounds. With a proven track record, Cerevance’s team believes it is well positioned to deliver life-changing therapeutics for patients who have brain-related disorders.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191126005468/en/
CONTACT: Cerevance Contact:
Robert Middlebrook, +1.408.220.5722Media Contact:
Andrew Mielach,email@example.com, +1.646.876.5868
KEYWORD: UNITED STATES NORTH AMERICA NEW YORK MASSACHUSETTS
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH OTHER HEALTH
Copyright Business Wire 2019.
PUB: 11/26/2019 10:17 AM/DISC: 11/26/2019 10:17 AM